Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The Cooperstown Cocktail is a standardized combination of five pharmaceutical drugs: midazolam, omeprazole, warfarin, caffeine, and dextromethorphan. It is primarily used as a phenotyping cocktail in clinical studies to simultaneously assess the activity of multiple drug-metabolizing enzymes, particularly various cytochrome P450 (CYP) isoforms, N-acetyltransferase-2 (NAT2), and xanthine oxidase (XO). Each component serves as a probe substrate for a specific enzyme, allowing researchers to evaluate drug-drug interactions and individual variability in drug metabolism. This cocktail is a valuable tool in pharmacokinetic research to understand how new drugs might affect or be affected by these metabolic pathways.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Cooperstown Cocktail.